Imiquimod attenuates the growth of UVB-Induced SCC in mice through Th1/Th17 cells

Molecular Carcinogenesis

Volumn 52, Issue 10, 2013, Pages 760-769

  Yokogawa, Maki ^a   Takaishi, Mikiro ^a   Nakajima, Kimiko ^a   Kamijima, Reiko ^a   Digiovanni, John ^b   Sano, Shigetoshi ^a  

^a KOCHI UNIVERSITY   (Japan)

^b University of Texas at Austin   (United States)

Author keywords

Th1 Th17; TLR agonist; UVB induced skin cancer

Indexed keywords

BESELNA CREAM; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 12; INTERLEUKIN 12P35; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23P19; INTERLEUKIN 23P40; MESSENGER RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; CREAM; DRUG EFFECT; FEMALE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; SKIN CANCER; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL; TRANSGENIC MOUSE; ULTRAVIOLET B RADIATION; UPREGULATION; WILD TYPE;

TH1/TH17; TLR AGONIST; UVB-INDUCED SKIN CANCER;

ADMINISTRATION, TOPICAL; AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; DENDRITIC CELLS; EPIDERMIS; IMMUNOENZYME TECHNIQUES; KERATINOCYTES; MICE; MICE, TRANSGENIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; TH1 CELLS; TH17 CELLS; ULTRAVIOLET RAYS;

MUS; MUS MUSCULUS;

EID: 84884815205     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21901     Document Type: Article

References (35)

1. Stockfleth E, Meyer T, Benninghoff B, Christophers E. Successful treatment of actinic keratosis with imiquimod cream 5%: A report of six cases. Br J Dermatol 2001; 144:1050-1053.
2. Persaud AN, Shamuelova E, Sherer D, et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol 2002; 47:553-556.
3. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: Results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51:547-555.
4. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44:807-813.
5. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: Randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147:1227-1236.
6. Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W. The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: An overview. Br J Dermatol 2003; 149:53-56.
7. Schon MP, Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008; 27:190-199.
8. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007; 204:1441-1451.
9. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441:431-436.
10. Gorden KB, Gorski KS, Gibson SJ, et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol 2005; 174:1259-1268.
11. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Cutting edge: Priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 2005; 174:2476-2480.
12. Prins RM, Craft N, Bruhn KW, et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: Relation to central nervous system antitumor immunity. J Immunol 2006; 176:157-164.
13. Palamara F, Meindl S, Holcmann M, Luhrs P, Stingl G, Sibilia M. Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod. J Immunol 2004; 173:3051-3061.
14. Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: Sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008; 8:594-606.
15. Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999; 191:10-19.
16. Conrad C, Meller S, Gilliet M. Plasmacytoid dendritic cells in the skin: To sense or not to sense nucleic acids. Semin Immunol 2009; 21:101-109.
17. van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009; 182:5836-5845.
18. Sano S, Chan KS, Kira M, et al. Signal transducer and activator of transcription 3 is a key regulator of keratinocyte survival and proliferation following UV irradiation. Cancer Res 2005; 65:5720-5729.
19. Sano S, Chan KS, DiGiovanni J. Impact of Stat3 activation upon skin biology: A dichotomy of its role between homeostasis and diseases. J Dermatol Sci 2008; 50:1-14.
20. Chan KS, Sano S, Kataoka K, et al. Forced expression of a constitutively active form of Stat3 in mouse epidermis enhances malignant progression of skin tumors induced by two-stage carcinogenesis. Oncogene 2008; 27:1087-1094.
21. Kim DJ, Angel JM, Sano S, DiGiovanni J. Constitutive activation and targeted disruption of signal transducer and activator of transcription 3 (Stat3) in mouse epidermis reveal its critical role in UVB-induced skin carcinogenesis. Oncogene 2009; 28:950-960.
22. Sano S, Chan KS, Carbajal S, et al. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005; 11:43-49.
23. Nakajima K, Kanda T, Takaishi M, et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol 2011; 186:4481-4489.
24. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: Systematic review and meta-analysis. J Invest Dermatol 2006; 126:1251-1255.
25. Lysa B, Tartler U, Wolf R, et al. Gene expression in actinic keratoses: Pharmacological modulation by imiquimod. Br J Dermatol 2004; 151:1150-1159.
26. Ooi T, Barnetson RS, Zhuang L, et al. Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: A randomized controlled trial. Br J Dermatol 2006; 154:72-78.
27. Urosevic M, Dummer R, Conrad C, et al. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment. J Natl Cancer Inst 2005; 97:1143-1153.
28. Bohm W, Thoma S, Leithauser F, Moller P, Schirmbeck R, Reimann J. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol 1998; 161:897-908.
29. Gilliet M, Conrad C, Geiges M, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004; 140:1490-1495.
30. Nickoloff BJ. Creation of psoriatic plaques: The ultimate tumor suppressor pathway. A new model for an ancient T-cell-mediated skin disease. Viewpoint. J Cutan Pathol 2001; 28:57-64.
31. Nickoloff BJ. The skin cancer paradox of psoriasis: A matter of life and death decisions in the epidermis. Arch Dermatol 2004; 140:873-875.
32. Paltiel O, Adler B, Herschko K, Tsukrov B, David M. Are patients with psoriasis susceptible to the classic risk factors for actinic keratoses? Arch Dermatol 2004; 140:805-810.
33. Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008; 112:362-373.
34. Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010; 10:248-256.
35. Maniati E, Soper R, Hagemann T. Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene 2010; 29:5653-5662.